Earticle

초록

영어

Purpose: The purpose of this study is to evaluate current criteria for insurance coverage by Health Insurance Review & Assessment Service (HIRA) on the systemic therapy used in the treatment of advanced or metastatic renal cell carcinoma (RCC), by reviewing all available clinical evidences including a variety of clinical practice guidelines. Methods:We searched clinical databases and collected data from published phase 1 through 3 randomized clinical trials on all systemic therapies used in RCC, including novel targeted therapies. Additionally, current clinical practice guidelines on the management of kidney cancer or RCC were reviewed. Based on the collected data we evaluated the appropriateness of the HIRA criteria for insurance coverage on the systemic therapy of RCC whether they are evidence-based and up to date. Results: On the basis of the collected data we concluded that there was a need for a revision in HIRA criteria for systemic therapy of RCC. Despite recent emerging therapeutic advances and changes in therapeutic strategies of management of RCC, some of anticancer regimens were inappropriately listed even though they were not proven to provide efficacy or safety superior to those of other therapies. We thus proposed an updated recommendation based on current clinical evidences. Conclusion: Systemic therapy of RCC is being rapidly changed with the advancement of understanding of the molecular biology of cancer. Consequently newly developed targeted therapies are becoming the standard therapy in the management of medically or surgically unresectable advanced or metastatic RCC. To provide effective and safe therapy to patients with RCC, the criteria for insurance coverage should be made carefully taking into consideration of most up-todate and high-quality clinical evidences, and should be continuously reviewed so as to reflect evidence-based clinical practice.

목차

Abstract
 연구방법
  연구대상 및 내용
  연구방법
 연구결과
  신장암에 사용되는 전신 항암요법의 국내 요양급여 기준
  신장암에 사용되는 전신 항암요법의 임상문헌 검토
  진행된 또는 전이성 신세포암의 임상 치료 가이드라인 검토
  신장암에 사용되는 항암화학요법의 임상적 유용성 및급여기준의 적절성 검토
 고찰 및 결론
 참고문헌

키워드

저자

• 김정연 [ Jeong Yeon Kim | 숙명여자대학교 약학대학 ]
• 박은지 [ Eun Ji Park | 숙명여자대학교 약학대학 ]
• 배민경 [ Min kyung Bae | 부산대학교 약학대학 ]
• 윤정현 [ Jeong-Hyun Yoon | 부산대학교 약학대학 ] Correspondence

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615